- Home
- ACHC vs ROIV Comparison
ACHC vs ROIV Comparison
Compare ACHC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | ROIV |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACHC | ROIV |
|---|---|---|
| Price | $14.20 | $21.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $24.38 | $21.94 |
| AVG Volume (30 Days) | 3.5M | ★ 6.7M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $3,265,548,000.00 | $20,329,000.00 |
| Revenue This Year | $6.50 | N/A |
| Revenue Next Year | $4.38 | $376.94 |
| P/E Ratio | $12.11 | ★ N/A |
| Revenue Growth | ★ 4.58 | N/A |
| 52 Week Low | $12.63 | $8.73 |
| 52 Week High | $47.08 | $22.45 |
Technical Indicators
Market Signals| Indicator | ACHC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 68.21 |
| Support Level | $13.60 | $20.14 |
| Resistance Level | $15.55 | $21.48 |
| Average True Range (ATR) | 0.95 | 0.66 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 31.52 | 87.12 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.